InMed Pharmaceuticals (CSE: IN, OTCQB: IMLFF) announced today that it has retained the consulting services of Ben Paterson, P.E., to assist in defining the pathway for the scale-up, purification, and manufacturing strategies for InMed’s cannabinoid biosynthesis program. |